Different value frameworks offer different things, as Alan Balch, PhD, CEO of the Patient Advocate Foundation, explained that each framework has various other objectives in mind. Balch differentiates frameworks based upon whether their objectives reach individual or population-based levels.
Different value frameworks offer different things, as Alan Balch, PhD, CEO of the Patient Advocate Foundation, explained that each framework has various other objectives in mind. Balch differentiates frameworks based upon whether their objectives reach individual or population-based levels.
Transcript (slightly modified)
These are a number of different value assessment frameworks that have been created (NCCN, ASCO, ICER). How can patients and providers differentiate between them?
I think there will be differences between them just naturally because they often have different points of departure in terms of what they’re trying to address. So, some are very purposefully designed to deliver information to one stakeholder community than another. So for example, ICER is very explicit about having the outcomes of their information really being geared towards policy makers and providers whereas the NCCN evidence blocks is really geared towards generating a conversation between the patient and the provider and ASCO’s value framework is similar.
So given a sort of form follows function, so given that they have different purposes, you are going to see naturally the methodologies and the way they’re constructed will be different, depending upon what the purpose is of that value tool. So I do think there will be differences and probably the biggest thing that leads to differences in them is at what scale are they trying to define value, or define a particular variable.
And to me, the two more natural stratifications, there are individual level versus population level. So for example, when the evidence blocks for NCCN talks about affordability, it’s really at the population scale whereas the ASCO value framework, when they really talk about cost, it’s literally a blank right now because it’s meant to be personalized to the individual. At least for cost at the cost variable in that framework is very individualized whereas in other frameworks, the cost variable is very much at the population level. And that will lead naturally to differences in how that information is conveyed to patients and what information goes into creating, populating that particular variable in the framework.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More